A Reference Article

Naftalan Oil Therapy
The Complete Guide

By Alexandr Umanetz·Updated May 2026·22 min read
I

What is naftalan?

Naftalan is a unique form of crude oil extracted only in the Naftalan region of Azerbaijan. Unlike petroleum used for fuel, naftalan is composed primarily of naphthenic hydrocarbons — over 50% by volume — giving it physical and biological properties not found in any other natural substance on earth.

Its distinctive dark-brown colour and characteristic odour come from these naphthenic compounds, which contemporary research suggests are responsible for the therapeutic effects observed over more than a century of clinical use. The oil is purified to remove light hydrocarbons before medical application, leaving behind the therapeutically active fraction known as deresined naftalan.

II

History & origins

The therapeutic use of naftalan dates to the late 19th century, when the local Azerbaijani population observed that bathing in the natural oil springs relieved joint pain and stubborn skin conditions. A German pharmacist, Egor Iegoroff, opened the region's first commercial extraction operation in 1890 and began exporting the oil to Europe.

The first state-run clinical sanatorium opened in Naftalan in 1926. During the Soviet era, the region became one of the most important medical resorts in the USSR, treating over 70,000 patients annually at its peak. Today, eight sanatoriums operate in the region, attended by patients from across Europe, the Middle East, and beyond.

III

The science: how it works

The proposed mechanism of action centres on transcutaneous absorption of naphthenic hydrocarbons during balneological treatment. These molecules are believed to interact with cell membranes, exerting anti-inflammatory and analgesic effects via modulation of prostaglandin pathways and reduction of pro-inflammatory cytokine expression.

Research conducted at the Naftalan Institute of Balneology (Azerbaijan, 2014–2019) and at clinical centres in Croatia (Ivanišević Spa, Daruvar) has documented measurable reductions in inflammatory markers, joint stiffness, and dermatological symptom scores following standard 10–14 day treatment courses.

IV

Conditions & indications

Naftalan therapy is documented for a range of musculoskeletal, dermatological, neurological, and vascular conditions. The strength of clinical evidence varies considerably by indication.

IndicationEvidenceCourse
Osteoarthritis (knee, hip)Moderate (RCTs)12–14 days
Rheumatoid arthritisModerate (controlled)14 days
Psoriasis vulgarisStrong (observational)10–12 days
Ankylosing spondylitisEmerging14 days
Eczema (chronic)Strong (observational)10 days
Peripheral vascular diseaseObservational12 days
V

Contraindications

Naftalan therapy is not appropriate for everyone. The following are absolute contraindications: active malignancy, acute infectious disease, severe cardiovascular insufficiency, decompensated diabetes, severe renal or hepatic impairment, active tuberculosis, pregnancy, and known hypersensitivity to petroleum-derived substances.

Relative contraindications include uncontrolled hypertension, recent surgery, and severe atopic conditions in acute flare. Every prospective patient should obtain medical clearance from their primary physician before booking treatment.

VI

The treatment protocol

A standard course of treatment lasts 10 to 14 days. Each day, the patient receives a single naftalan bath — typically 8 to 10 minutes in duration, at body temperature (36–38°C). Baths are administered under medical supervision; vital signs are monitored before and after each session.

Adjunct therapies frequently include therapeutic massage, mud applications, mineral water consumption, and physiotherapy. The total programme is designed by the sanatorium's medical staff based on each patient's specific indication and overall condition.

VII

What to expect

Most patients report a sensation of warmth and mild tingling during their first few baths. Many describe an initial worsening of symptoms — the so-called balneological reaction — typically around days three to five, followed by progressive improvement.

Full therapeutic benefit usually emerges 4 to 8 weeks after the end of the treatment course. Patients are advised to maintain a follow-up consultation with their physician at home and to document outcomes for future reference.

VIII

Research & clinical evidence

The most robust contemporary evidence for naftalan therapy comes from controlled studies on rheumatoid arthritis, psoriasis, and osteoarthritis of the knee. Smaller observational studies cover ankylosing spondylitis and peripheral vascular disease.

The complete bibliography — including primary clinical sources, review articles, and the original Soviet-era research — is maintained in the Research section of this site.

References
  1. Krnjevic-Pezic G., Alajbeg I., Maricic G., Pasic A., Curkovic B., Ceovic R., Kostovic K. "Naphthalan oil in the treatment of psoriasis and psoriatic arthritis." Journal of Dermatological Treatment, 2012. https://journals.sagepub.com/doi/abs/10.1177/247553031218a00104
  2. Alajbeg I., et al. "Non-aromatic naphthalane preparation; preliminary clinical study in the treatment of psoriasis vulgaris." Journal of Pharmaceutical and Biomedical Analysis, 2001; 26: 801–9. https://www.sciencedirect.com/science/article/abs/pii/S0731708501004587
  3. Vrzogic P., Jakic-Razumovic J., Pasic A. "Effects of naphthalan on epidermal proliferation activity and CD3, CD4 and CD8 lymphocyte count." Acta Dermatovenerologica Croatica, 2003; 11: 65–9.
  4. Vrzogic P., Jakic-Razumovic J., Lipozencic J. "Naphtalanotherapy reduces angiogenic factor in psoriatic lesions." Acta Dermatovenerologica Croatica, 2004; 12: 7–11.
  5. Krnjevic-Pezic G., et al. "Effect of naphthalene therapy on proliferative activity, CD4 and CD8 cell count, apoptosis and angiogenesis in the skin of patients with psoriasis." British Journal of Dermatology, 2006; 154: 21–2.
  6. Alajbeg I., et al. "Naphthalan — a natural medicinal product." Collegium Antropologicum, 2003. PubMed PMID: 12967511. https://pubmed.ncbi.nlm.nih.gov/12967511/
  7. Alajbeg I., et al. "NAVS naphthalan for the treatment of oral mucosal diseases — a pilot study." Journal of Oral Pathology & Medicine, 2015. PubMed PMID: 25580784. https://pubmed.ncbi.nlm.nih.gov/25580784/
  8. Alajbeg I., et al. "Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: a double blind, randomized, parallel group study." PLOS ONE, 2021. PMC8031371. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031371/
  9. Safixanova X.M., et al. "Naftalan oil is a specific balneological factor of Azerbaijan." Azerbaijan Journal of Physiology, Vol. 38, No. 1, pp. 48–56, 2023. https://www.researchgate.net/publication/372269371
  10. Abbasov V.M., Isayeva G.A., Aliyev F.Sh., et al. "Analysis of scientific results on the study of therapeutic Naftalan oil." Institute of Petrochemical Processes, ANAS, 2024. https://www.researchgate.net/publication/385936488
  11. Abbasov V.M. "Historical facts on the study of the physicochemical properties and structural-group composition of therapeutic Naftalan oil." Baku: Elm, 2009.
  12. Movsumova P.A. "The role of ionic liquid morpholine formiate as an extractant in selective treatment of 260–340°C fraction therapeutic Naftalan oil." International Journal of Advance Engineering and Research Development, 6(1): 40–43, 2019.
  13. "About naphthenic oil and aspects of its healing properties." Azerbaijan Chemical Journal, 2024. doi: 10.32737/0005-2531-2024-114-126. https://akj.az/en/journals/1052
  14. Verhagen A.P., Bierma-Zeinstra S.M., Boers M., et al. "Balneotherapy (or spa therapy) for rheumatoid arthritis." Cochrane Database of Systematic Reviews, 2015; (4): CD000518. PubMed PMID: 25862243. https://pubmed.ncbi.nlm.nih.gov/25862243/
  15. "A review of scientific research on therapeutic Naftalan oil." ResearchGate, 2025. https://www.researchgate.net/publication/394133217